Biomea Fusion, Inc. (BMEA) vs Citius Oncology, Inc. (CTOR)
A side-by-side comparison of Biomea Fusion, Inc. and Citius Oncology, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BMEA
Biomea Fusion, Inc.
$1.25HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
CTOR
Citius Oncology, Inc.
$0.85HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — BMEA vs CTOR
growth of $100 · dividends reinvested · last 2yBMEA -76.7% (-51.7%/yr)CTOR -92.4% (-72.4%/yr)BMEA compounded faster over this window
BMEA CTOR
BMEA vs CTOR: by the numbers
- •BMEA is the larger company ($90M vs $79M market cap).
- •Both run net losses; BMEA's is the smaller (0.00% vs -648.32% net margin).
Metrics side by side
Valuation
| Metric | BMEA | CTOR |
|---|---|---|
| Forward P/E | N/A | 8.50 |
| P/S ratio | N/A | 11.12 |
| P/B ratio | 7.45 | 1.96 |
Profitability
| Metric | BMEA | CTOR |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | -648.32% |
| ROE | -268.09% | -114.06% |
| ROIC | -220.02% | -88.72% |
Growth (annualized)
| Metric | BMEA | CTOR |
|---|---|---|
| Total return CAGR (5Y) | -36.56% | N/A |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.